Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma

被引:73
作者
Karimova, Evguenia J.
Rai, Shesh N.
Howard, Scott C.
Neel, Michael
Britton, Lunetha
Pui, Ching-Hon
Kaste, Sue C.
机构
[1] St Jude Childrens Hosp, Div Diagnost Imaging & Biostat, Memphis, TN 38105 USA
[2] St Jude Childrens Hosp, Dept Radiol Sci, Memphis, TN 38105 USA
[3] St Jude Childrens Hosp, Int Outreach Program, Memphis, TN 38105 USA
[4] St Jude Childrens Hosp, Div Orthoped, Memphis, TN 38105 USA
[5] St Jude Childrens Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA
[6] Univ Tennessee, Sch Med, Dept Radiol, Memphis, TN USA
关键词
D O I
10.1200/JCO.2006.07.9947
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Osteonecrosis of the capital femoral epiphysis is a significant late toxicity of treatment for childhood leukemia and lymphoma. We determined clinical and imaging risk factors predicting clinical joint outcomes of femoral head osteonecrosis in pediatric patients with leukemia or lymphoma. Patients and Methods We reviewed retrospectively medical records and magnetic resonance imaging scans of 80 patients with osteonecrosis of the capital femoral epiphysis. Logistic regression was used to examine relationships between risk factors and outcomes of joint surface collapse and arthroplasty. We used Kaplan-Meier survival curves to display the time to joint surface collapse and arthroplasty based on selected predictors. Results Median time between primary diagnosis and diagnosis of osteonecrosis of the hip was 1.7 years (range, 0.1 to 17.5 years). Twenty-three patients (29%) underwent arthroplasty in 36 hips at a mean of 1.3 years (range, 0.5 to 8.6 years) after diagnosis of osteonecrosis. Median age at time of first arthroplasty was 20.1 years (range, 15.1 to 35.4 years). Joint outcome of osteonecrosis was predicted solely by lesion size at diagnosis of osteonecrosis. The worst prognosis was associated with lesions occupying more than 30% of the femoral head volume; 80% of hips with these lesions collapsed within 2 years of diagnosis and 50% required arthroplasty. Conclusion Lesion size of osteonecrosis is the best predictor of clinical joint outcome of hip osteonecrosis in survivors of pediatric hematologic malignancy. Lesions occupying more than 30% of the femoral head have high likelihood of joint deterioration necessitating arthroplasty at a young age.
引用
收藏
页码:1525 / 1531
页数:7
相关论文
共 26 条
[1]  
Aricò M, 2003, HAEMATOLOGICA, V88, P747
[2]  
BALDUZZI A, 1995, BLOOD, V86, P3247
[3]   Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group [J].
Bostrom, BC ;
Sensel, MR ;
Sather, HN ;
Gaynon, PS ;
La, MK ;
Johnston, K ;
Erdmann, GR ;
Gold, S ;
Heerema, NA ;
Hutchinson, RJ ;
Provisor, AJ ;
Trigg, ME .
BLOOD, 2003, 101 (10) :3809-3817
[4]   Osteonecrosis:: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) -: Experiences from trial ALL-BFM 95 [J].
Bürger, B ;
Beier, R ;
Zimmermann, M ;
Beck, JD ;
Reiter, A ;
Schrappe, M .
PEDIATRIC BLOOD & CANCER, 2005, 44 (03) :220-225
[5]   THE USE OF GLUCOCORTICOIDS IN ACUTE LYMPHOBLASTIC-LEUKEMIA OF CHILDHOOD - MOLECULAR, CELLULAR, AND CLINICAL CONSIDERATIONS [J].
GAYNON, PS ;
LUSTIG, RH .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1995, 17 (01) :1-12
[6]   Volumetric analysis of osteonecrosis of the femur - Anatomical correlation using MRI [J].
Hernigou, P ;
Lambotte, JC .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2001, 83B (05) :672-675
[7]   Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia [J].
Ito, C ;
Evans, WE ;
McNinch, L ;
CoustanSmith, E ;
Mahmoud, H ;
Pui, CH ;
Campana, D .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2370-2376
[8]   Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation [J].
Kaste, SC ;
Shidler, TJ ;
Tong, X ;
Srivastava, DK ;
Rochester, R ;
Hudson, MM ;
Shearer, PD ;
Hale, GA .
BONE MARROW TRANSPLANTATION, 2004, 33 (04) :435-441
[9]  
Korholz D, 1998, PEDIATR HEMAT ONCOL, V15, P307
[10]  
Letson GD, 1996, ORTHOPEDICS, V19, P665